Phaseline

Companies › Purespring Therapeutics

Purespring Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Genitourinary; next expected readout Sep 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PS-002
Adeno-associated viral vector delivering Complement Factor I (CFI) gene to correct complem
CFIPhase 1Immunoglobulin A (IgA) NephropathySep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07182227PS-002Phase 1Immunoglobulin A (IgA) NephropathyGenitourinarySep 2028

Targets

CFI (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.